^
Association details:
| Biomarker: | CD20 positive |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) + lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) + Epkinly (epcoritamab-bysp) (CD20 inhibitor, CD3 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
Published date:
11/03/2022
Excerpt:
Adults with R/R CD20+ FL were treated with subcutaneous epcoritamab 48 mg + standard R2 for 12 cycles of 28 d each….Data from this cohort are very encouraging with a high CMR rate observed in patients with R/R FL.
DOI:
10.1182/blood-2022-158203
Trial ID:
Source:
Title:
Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial
Published date:
11/03/2022
Excerpt:
Adults with previously untreated CD20+ FL grade 1–3A who met GELF criteria for treatment were enrolled and received subcutaneous epcoritamab 48 mg + R2 for 12 cycles of 28 d each….Among efficacy-evaluable patients (n=29), the overall response rate was 90% (26/29), with 69% (20/29) having a complete metabolic response (CMR) as their best overall response.
DOI:
10.1182/blood-2022-158232
Trial ID:
Source:
Title:
3535 Subcutaneous Epcoritamab in Combination with R2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial
Published date:
11/04/2021
Excerpt:
Adults with histologically confirmed R/R CD20+ FL received epcoritamab in a dose-escalation phase followed by an expansion phase at the recommended phase 2 dose in combination with R2 for 12 cycles (28 days/cycle)....Five pts completed at least 6 weeks of therapy and were evaluable for efficacy....CRS occurred in 31% of pts (5/16) and all cases were of grade 1/2. The median time to onset of CRS was 15 days (study day 16; range, 5–16) and median time to resolution was 2 days....All 5 response-evaluable pts achieved an objective response by week 7, with 4 achieving complete metabolic response.
